ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2026
ImmuCell (Nasdaq: ICCC) expects to report unaudited third-quarter financial results after the market closes on November 12, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
ImmuCell (Nasdaq: ICCC) expects to report unaudited third-quarter financial results after the market closes on November 12, 2026. The results cover the quarter ended September 30, 2026; its Form 10-Q is also expected that evening.
The company plans a November 13, 2026 webcast and conference call at 9:00 AM ET and anticipates no change to preliminary quarterly sales results disclosed on October 12, 2026.
Key Figures
- Results reporting date
- November 12, 2026 after market close
- Unaudited results for the quarter ended September 30, 2026
Key Terms
form 10-q regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Conference Call Scheduled for Friday, November 13, 2026 at 9:00 AM ET
PORTLAND, Maine, Nov. 06, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity, expects to report unaudited financial results for the quarter ended September 30, 2026 after the market closes on Thursday, November 12, 2026.
The Company is planning to host a conference call and webcast on November 13, 2026, at 9:00 AM ET to review the unaudited financial results. Interested parties may access the conference call by dialing (844) 855-9502 (toll free) or (412) 317-5499 (international).
The live webcast can be accessed at: https://app.webinar.net/JL8AEda3K5D
The live webcast will feature a set of accompanying presentation slides that will subsequently be available in the Investors section of the Company’s website at: https://immucell.com/investors/
A teleconference replay of the conference call will be available through November 20, 2026, by dialing (855) 669-9658 (toll free) or (412) 317-0088 (international) and utilizing replay access code #2589057.
The Company anticipates no change to the preliminary sales results for the quarter ended September 30, 2026 that were disclosed on October 12, 2026. The Company expects to file its Quarterly Report on Form 10-Q on November 12, 2026 after the market closes.
About ImmuCell:
ImmuCell Corporation (Nasdaq: ICCC) is an animal-health biologics company that operates in the fast-growing market for calf health solutions. It develops, manufactures and commercializes the First Defense® line of products that provides Immediate Immunity™ through colostrum-derived, orally delivered antibodies against the principal viral and bacterial causes of scours. Scours (neonatal calf diarrhea) is one of the most prevalent and deadly diseases in neonatal calves worldwide. Press releases and other information about the Company are available at: http://www.immucell.com/investors.
| Contacts: | Olivier te Boekhorst, President and CEO |
| Timothy C. Fiori, Chief Financial Officer | |
| ImmuCell Corporation | |
| investor.relations@immucell.com | |
| Joe Diaz, Robert Blum and Joe Dorame | |
| Lytham Partners, LLC | |
| iccc@lythampartners.com |
